Scancell Holdings Plc · LSE:SCLP
Scancell — Investor Presentation (March 2012)
22 slides from Scancell's investor presentation, Mar 13, 2012
Slide 1: AIM-listed clinical stage biotech company
AIM-listed clinical stage biotech company David Evans 13th March 2012 Dr Richard Goodfellow Professor Lindy Durrant 1
Slide 2: Disclaimer
Disclaimer This document is issued by Scancell Holdings plc (the “Company”), has been prepared solely for information purposes and is the sole responsibility of the directors of the Company. To the best of the knowledge and belief of the directors of the Company, who have taken all reasonable care t
Slide 3: David Evans, Non-Executive Chairman
David Evans Non- Executive Chairman 3
Slide 4: Dr Richard Goodfellow, Co-Chief Executive
Dr Richard Goodfellow Co-Chief Executive 4
Slide 5: Company Overview
Company Overview Clinical stage immunotherapy company with novel ‘ImmunoBody’ DNA vaccine platform for cancer and chronic infectious diseases Lead product (SCIB1 for melanoma) entered Phase I clinical trials in June 2010 with steady progress made in 2011 -Dose increased from 0.4mg to 4mg with no ser
Slide 6: Industry Trends
Industry Trends Continued trend for Big Pharma to move away from in-house R&D and to rely more on partnerships with Industry and Academia Larger Biotechs becoming more aggressive buyers of innovative companies and providing growing competition for Big Pharma Pick up in M&A deal value in 2011 (e.g. A
Slide 7: Cancer Vaccine Sales Increasing
Cancer Vaccine Sales Increasing 7
Slide 8: A Year of Steady Progress
A Year of Steady Progress Patient recruitment for Phase 1 trial of SCIB1 in melanoma completed Dose escalation to highest dose of 4mg achieved with no serious adverse effects Follow up vaccine for lung and other cancers (SCIB2) produces outstanding results in animal studies Additional £1.73m (gross)
Slide 9: Share Information
Listing on AIM Share Information October 2011 Placing £1.58m raised Milestone payment of £2.85m from Share Cephalon Inc Price received (10 for 1 Subdivision of Shares occurred 25 July 2011) Market Capitalisation at 1st January 2008- 2012 £1.6m April 2010 raised in Placing PLUS float £2.5m raised Thi
Slide 10: Strategy on Track
Strategy on Track Validation of ImmunoBody platform through - Clinical data on SCIB1 - Phase 1 data 2012 - Phase 2 data 2013 - Pre-Clinical data on new ImmunoBody vaccines - New supporting technologies Trade sale to large pharmaceutical or biotech company 10
Slide 11: Professor Lindy Durrant, Co-Chief Executive
Professor Lindy Durrant Co- Chief Executive 11
Slide 12: SCIB1 (melanoma)
SCIBI (melanoma) High avidity CD8 and CD4 response Better than synthetic peptide or whole antigen Better than DNA antigen immunisation Similar to DC vaccines Works with gene gun, id/im electroporation Induces anti-tumour activity in vivo GMP manufactured No Toxicity Metheringham et al., 2009 mabs CT
Slide 13: Ichor TRIGRID Delivery System
Ichor TRIGRID™ Delivery System Uses electrical fields to increase DNA drug delivery efficiency Electrode array consists of four electrodes in a diamond-shaped grid around a central injection needle Simple hand-held device developed for use in humans Can deliver equivalent does in man to mouse Im eas
Slide 14: Phase I-II trial in stage IV/III melanoma
Phase I-II trial in stage IV/III melanoma Primary Objective: Start: June 2010safety and tolerability To demonstrate Secondary Objective: To demonstrate cellular immune response (high avidity T-cells) and tumour response Phase One • 9 patients • 3 subjects per cohort; 0.4mg, 2.0 mg or 4.0 mg • Progre
Slide 15: Phase I-II trial in stage III/IV melanoma
Phase I-II trial in stage III/IV melanoma • GTAC approval for the trial was given in May 2010 and the first patient was immunised in June 2010 • 5 centres: Nottingham, Manchester, Newcastle, Leeds and Southampton • Phase I fully recruited – no toxicity • Phase II starting 2 Q 2012 • Phase I complete
Slide 16: SCIB2-NYESO-1
• Vaccine encodes 20 epitopes SCIB2-NYESO-1 covers 90-100% of population • Expressed by lung (SCLC), melanoma, • Better than peptide oesophageal, liver, • Better than Dc peptide (Dendreo gastric, prostate, ovarian and bladder cancers •Improves survival P=0.044 p=0.0041 p=0.0003 1E-10 1E-09 1E-08 1E-
Slide 17: Candidate for SCIB3?
Candidate for SCIB3? • Novel patentable target (Patents being prepared) • Widely expressed ( lung , ovarian , renal, leukaemias, sarcomas, melanoma, oesophageal, liver, gastric and prostate cancers) • Novel CD4 self epitope stimulates killer CD4 T cells • Potent anti-tumour response 17
Slide 18: Summary
Summary • Phase I recruited • Phase II due to start April 2012 • SCIB2 NYESO-1 good anti-tumour response • SCIB3 new patent good anti-tumour response 18
Slide 19: Appendix
Appendix mY,
Slide 20: Board of Directors
Board of Directors David Evans (Non-Executive Chairman) Guided Shield Diagnostics Ltd through IPO, and then through its merger with Axis Biochemical ASA to form Axis-Shield plc. Non-executive Chairman of Epistem Holdings plc, Omega Diagnostics Group plc and EKF Diagnostics Holdings plc, all AIM-list
Slide 21: Key Facts & Major Shareholders
Key Facts & Major Shareholders Ticker SCLP % of Stock Exchange AIM Issued Share Shares in Issue 194m Capital Share Price 6.5p HSBC Global Custody 13.00 Sector Pharmaceuticals Nominee & Biotechnology New Edge Group SA 9.04 Hygea VCT Plc 7.63 Year Year Professor Lindy Durrant 5.39 ende ende d d J G He
Slide 22: Glossary
Glossary Antibodies Proteins found in blood or other bodily fluids of vertebrates, used by the immune system to identify and neutralize foreign objects, such as tumours Antigen A molecule that is recognised by an antibody or T-cell receptor Avidity How strongly two cells interact Dendritic cells A t
Scancell Holdings — Investor Presentation (March 2012) on 6ix